A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma (HCC)

PURPOSE: Sorafenib is a standard first-line treatment for advanced HCC. The phase III SHARP trial showed a median time-to-progression(mTTP) of 5.5 months, overall response rate(ORR) of 2%, and median overall survival(mOS) of 10.7 months with sorafenib. FOLFOX4 has shown modest activity in advanced H...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Goyal, Lipika, Zheng, Hui, Abrams, Thomas A., Miksad, Rebecca, Bullock, Andrea J., Allen, Jill N., Yurgelun, Matthew B., Clark, Jeffrey W., Kambadakone, Avinash, Muzikansky, Alona, Knowles, Michelle, Galway, Aralee, Afflitto, Anthony J., Dinicola, Caroline F., Regan, Eileen, Hato, Tai, Mamessier, Emilie, Shigeta, Kohei, Jain, Rakesh K., Duda, Dan G., Zhu, Andrew X.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6320284/
https://ncbi.nlm.nih.gov/pubmed/30190369
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0847
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados